{
  "id": 21032528,
  "title": "Legend Biotech CEO Ingrid Zhang purchases $163,200 in shares",
  "url": "https://urgent.news/2026/11/21/legend-biotech-ceo-ingrid-zhang-purchases-163-200-in-shares",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-21T10:31:17.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/legend-biotech-ceo-ingrid-zhang-purchases-163200-in-shares-93CH-5043358"
  },
  "original_language": "en",
  "account": "Legend Biotech Corp (NASDAQ:LEGN) CEO Ingrid Zhang acquired ordinary shares of the company on November 17, 2026, purchasing 20,000 shares at $8.16 per share, which amounts to a total investment of $163,200. This insider purchase is particularly noteworthy given the current stock price of $15.25, close to the 52-week low of $15.14, following a decline of nearly 46% over the past year.\n\nFollowing the acquisition, Zhang holds a total of 1,151,860 ordinary shares of Legend Biotech Corp. Analysts have deemed the stock undervalued at present, with the company listed on InvestingPro’s Most Undervalued list. For those interested in a more in-depth analysis, the company’s Pro Research Report is available for Legend Biotech and over 1,400 other US equities.\n\nIn recent news, Legend Biotech reported its Q3 2026 financial results, which included a revenue of $359.5 million, slightly exceeding Wall Street’s expectations of $358.63 million. However, the earnings per share were a loss of $0.13, considerably missing the forecasted loss of $0.0037. Despite the earnings miss, the company reported a 36% year-over-year increase in CARVYKTI net trade sales, reaching $710 million for the quarter. Furthermore, Legend Biotech upgraded its fourth-quarter product gross-margin outlook to the high-50% range.\n\nH.C. Wainwright maintained a Buy rating for Legend Biotech, with a price target of $65.00. The firm highlighted the company’s advancements in reaching half of the U.S. Carvykti apheresis for second- and third-line patients. These developments suggest a mixed financial performance, but also point towards potential growth areas for the company.",
  "summary": null,
  "key_points": [
    "Legend Biotech CEO Ingrid Zhang bought 20,000 shares at $8.16 each.",
    "Purchase totaled $163,200, increasing her stake to 1,151,860 shares.",
    "Analysts consider stock undervalued, citing 52-week low of $15.14."
  ],
  "editors_take": "The CEO's decision to buy shares near a fifty-two week low signals internal confidence in the company's long-term value despite recent earnings misses and significant stock price declines.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}